The Search for Better Hair: Why I'm Trying Calecim Professional

There are very few subjects in men's wellness that inspire quite the same combination of anxiety, experimentation and commercial opportunity as hair loss.

We are living through a golden age of personal health technology. We can monitor our cardiovascular health from our wrists, quantify our sleep, measure our training load and build increasingly sophisticated routines around the pursuit of longevity. Yet when it comes to something as visible, personal and psychologically significant as our hair, the experience can feel remarkably old-fashioned.

You notice your hairline changing. Perhaps the temples are beginning to recede, the crown looks a little thinner under certain lighting, or your hair no longer has the density it once did. You start paying attention to photographs. You notice the way your hair sits after a shower. Eventually, something that was once entirely unremarkable becomes a daily consideration.

Then begins the research.

You discover that male pattern baldness is remarkably common. You learn about dihydrotestosterone, or DHT, and the genetic susceptibility of hair follicles. You encounter finasteride, minoxidil, laser devices, microneedling, platelet-rich plasma, hair transplants and an almost endless assortment of supplements and topical formulations.

Some treatments have substantial clinical evidence behind them. Others have interesting preliminary research. And some seem to rely more heavily on persuasive marketing than convincing science.

The difficulty is that even the treatments with the strongest evidence come with considerations that deserve serious thought. For many men, the prospect of committing to a medication indefinitely, while weighing its potential side effects, is not an entirely straightforward decision.

This is where my interest in hair restoration has increasingly intersected with my broader fascination with longevity and regenerative medicine.

I am interested in treatments that have a plausible biological mechanism, credible supporting evidence and a sensible safety profile. I want to understand not simply whether something might work, but how it works, how well it has been studied and whether the results justify the investment.

That is what led me to Calecim Professional and its Advanced Hair System, a six-week programme built around its proprietary PTT-6 technology.

I am now one week into the programme.

I have six weeks of treatment ahead of me, and I intend to document the process properly: the routine, the experience, the changes I can actually observe and, just as importantly, the limitations of what I can conclude.

I am not going to pretend that a week is enough to judge a hair-loss treatment. It isn't. Nor am I going to promise that a regenerative serum will reverse a condition as complex as androgenetic alopecia.

But I do think the science behind Calecim is interesting enough to warrant a closer look.

This is the beginning of that investigation.

Why hair loss becomes more than a cosmetic concern

Hair is an interesting feature of human biology because its physical importance and psychological significance are not always proportionate.

From a physiological perspective, scalp hair offers some protection against ultraviolet radiation and contributes to temperature regulation. But for most men, its importance extends well beyond those functions.

Hair influences how we perceive our appearance, how we present ourselves and, sometimes, how we feel about ageing.

I am particularly interested in the intersection between appearance and longevity. We increasingly understand that healthy ageing is not simply about avoiding disease; it is also about maintaining the physical characteristics, confidence and quality of life that help us feel like ourselves.

Hair loss sits within that conversation.

It is important not to suggest that every man should treat hair loss or that a receding hairline represents a medical failure. Male pattern baldness is a normal, common biological process, and plenty of men are perfectly comfortable allowing it to progress naturally.

But for those who want to preserve their hair, the experience can be frustrating.

The process is often gradual. You may not notice a dramatic change from one month to the next, yet photographs taken several years apart can reveal a difference that is difficult to ignore.

Androgenetic alopecia, the medical term for male pattern baldness, is influenced by genetics and androgen signalling. In susceptible follicles, DHT contributes to a progressive process known as follicular miniaturisation.

Over successive hair cycles, affected follicles produce progressively finer, shorter hairs. Hair density decreases, the scalp becomes more visible and some follicles may eventually produce hairs that are barely noticeable.

The pattern usually involves the frontal hairline, temples and crown, although the distribution and rate of progression vary considerably.

The American Academy of Dermatology notes that male pattern hair loss can begin relatively early in adulthood and tends to progress over time. Earlier treatment can be beneficial because preserving existing follicles is generally more straightforward than attempting to restore hair that has been lost for a prolonged period.

That last point is particularly important.

Hair restoration is not simply about stimulating new growth. It is also about understanding the underlying cause of the loss, preserving what remains and choosing an approach that can realistically be maintained.

Understanding the biology: why men lose their hair

To understand why Calecim interests me, it helps to understand why conventional treatments work and why hair restoration is biologically complicated.

Each hair follicle operates through a repeating cycle consisting of several stages.

Anagen — the growth phase. The follicle actively produces a hair shaft. Scalp hair can remain in this phase for several years.

Catagen — the transition phase. Growth slows, and the follicle undergoes a controlled period of regression.

Telogen — the resting phase. The follicle remains relatively inactive before the hair is shed and a new growth cycle begins.

These phases do not occur simultaneously across the scalp. Different follicles occupy different stages at any given time, which is why healthy hair does not all fall out at once.

In androgenetic alopecia, however, susceptible follicles gradually change how they behave. Their growth phases can become shorter, the hairs they produce become thinner, and the overall cycle becomes progressively less productive.

This is why male pattern baldness cannot be understood simply as a problem of insufficient nutrients or a scalp that needs better moisturisation.

The underlying biology involves genetic susceptibility, androgen signalling, follicular responses and the local environment surrounding the hair follicle.

The role of DHT

DHT is produced when the enzyme 5-alpha-reductase converts testosterone into a more potent androgen.

In genetically susceptible hair follicles, DHT signalling contributes to miniaturisation. The same hormone does not produce the same effect in every hair follicle, which helps explain why men can develop different patterns of hair loss.

This mechanism is central to understanding finasteride.

Finasteride inhibits type II 5-alpha-reductase, reducing DHT production. By reducing the hormonal signal associated with follicular miniaturisation, it can slow the progression of male pattern hair loss and, in some men, promote regrowth.

It addresses an important part of the underlying process rather than simply attempting to improve the appearance of the hair shaft.

That is one reason it has a stronger evidence base than many newer hair-restoration products.

But the biology also explains why a treatment that supports the scalp environment may not necessarily have the same effect as a medication that reduces DHT.

A product can potentially improve hair thickness, scalp condition or aspects of follicular function without directly addressing the hormonal mechanism driving androgenetic alopecia.

That distinction will be central to how I evaluate Calecim.

The conventional treatments: what works, and what gives me pause?

My interest in hair care has never been limited to finding a shampoo that makes my hair feel thicker.

I have been interested in the treatments that might actually influence hair retention and growth. That inevitably leads to two names that dominate the discussion: finasteride and minoxidil.

They are not interchangeable, and they work through different mechanisms.

Finasteride: addressing the hormonal mechanism

Finasteride is one of the most established pharmaceutical treatments for male pattern baldness.

By reducing DHT production, it helps address the hormonal process that contributes to follicular miniaturisation in susceptible men.

Clinical evidence supports its ability to slow further hair loss, and some men experience meaningful regrowth. The American Academy of Dermatology reports that approximately 80–90% of men taking finasteride in the studies it cites experience a slowing of further hair loss. Results typically require months rather than weeks, and continued treatment is generally needed to maintain the benefit.

The appeal is obvious: a treatment that targets a central mechanism of the condition.

But the decision is not entirely straightforward.

Recognised adverse effects include reduced libido, erectile dysfunction and ejaculatory problems. Breast tenderness or enlargement and mood-related symptoms have also been reported. Regulators have issued additional warnings concerning depression and suicidal thoughts associated with finasteride, particularly in relation to oral formulations.

The UK Medicines and Healthcare products Regulatory Agency has emphasised that patients should be informed about psychiatric and sexual adverse effects and should seek medical advice if concerning symptoms develop.

These risks need to be discussed proportionately. Not every man experiences side effects, and the existence of a risk does not automatically make a treatment inappropriate.

Equally, they should not be dismissed simply because finasteride can be effective.

For me, the broader question is how to balance efficacy, tolerability, personal priorities and the commitment involved in long-term treatment. That is a conversation to have with a qualified prescriber, not a decision that should be made from online testimonials alone.

Minoxidil: encouraging growth through a different pathway

Minoxidil approaches hair loss differently.

Topical minoxidil is thought to promote hair growth through several mechanisms involving the hair follicle and its growth cycle. Its precise mechanism in androgenetic alopecia is not completely understood, but clinical evidence supports its use for stimulating growth and improving hair density in some men.

It does not directly inhibit DHT in the way finasteride does.

That distinction is important. Minoxidil can support growth without directly addressing the androgen-driven process that causes follicular miniaturisation.

Potential adverse effects of topical minoxidil include scalp irritation, itching, redness and unwanted hair growth outside the intended treatment area. Some users experience an initial increase in shedding as the hair cycle changes. More significant symptoms, including dizziness, palpitations or swelling, warrant prompt medical assessment.

Oral minoxidil is sometimes prescribed off-label for hair loss, but it has a different risk profile and should not be treated as equivalent to the topical formulation. It can cause fluid retention, changes in heart rate and low blood pressure, among other potentially serious adverse effects.

The practical consideration is also significant: minoxidil needs to be used consistently, and benefits generally diminish after treatment stops. Visible improvement can take six to twelve months.

For someone interested in a relatively low-maintenance routine, that ongoing commitment is worth considering.

It does not mean minoxidil is a bad treatment. It means that effectiveness is only one part of the decision.

Why I continue to look for alternatives

I want to be precise about my motivation here.

I am not suggesting that conventional treatments are ineffective or that their risks make them unsuitable for everyone. For many men, finasteride and minoxidil remain the best-supported options.

My interest in Calecim comes from a different question: are there complementary approaches that may support hair quality and follicular function without relying on exactly the same mechanisms?

That is a scientifically legitimate question.

But it also comes with a responsibility to distinguish an interesting alternative from a proven replacement.

At present, I would not regard Calecim as a clinically established substitute for finasteride or minoxidil in the management of male pattern baldness. The evidence supporting the latter treatments is more mature, and Calecim's published findings need to be interpreted within the context of its particular formulation and studies.

The reason I am willing to investigate it is not that I have concluded it is superior. It is that its proposed mechanism is interesting, and I want to understand whether the available evidence supports the claims.

Beyond medications: the wider hair-restoration landscape

Once you begin researching hair loss, the number of options expands rapidly.

Some treatments aim to alter hormonal signalling. Others attempt to stimulate follicular activity, improve the scalp environment or replace hair that has already been lost.

Understanding the differences helps put Calecim into perspective.

Low-level light therapy

Low-level light therapy, sometimes called photobiomodulation, uses specific wavelengths of light delivered by devices such as laser caps, helmets or combs.

Some clinical trials suggest that certain devices can improve hair density in people with androgenetic alopecia. Results vary by device, treatment protocol and study design, and the evidence is not equivalent to that supporting every established medication.

The attraction is that treatment can be performed at home without taking a systemic medication.

The disadvantages include cost, regular use and uncertainty about the magnitude and durability of the benefit for an individual.

I find this category interesting because it illustrates the wider direction of hair restoration: trying to influence follicular biology without relying exclusively on pharmaceutical interventions.

Microneedling

Microneedling involves creating controlled micro-injuries in the skin using a specialised device.

It has been investigated as an adjunct to hair-loss treatments, particularly minoxidil. Some studies suggest that combining microneedling with conventional treatment may improve outcomes compared with medication alone.

However, protocols vary, and microneedling is not risk-free. Inappropriate use can cause irritation, infection, bleeding, inflammation or scarring.

It is particularly important to distinguish professional procedures from aggressive at-home use.

Calecim's Advanced Hair System includes a scalp-preparation activator and an application process involving a derma-stamping device. That makes it important to follow the specific instructions supplied with the system and understand that some risks may arise from the application method as well as from the serum itself.

Platelet-rich plasma

Platelet-rich plasma, or PRP, involves taking a sample of a person's blood, processing it to concentrate platelets and injecting the resulting preparation into the scalp.

Platelets release a range of signalling molecules involved in tissue repair. The theory is that these molecules may help support the local environment around hair follicles.

Some clinical studies have reported improvements in hair density, but protocols differ substantially and the evidence remains heterogeneous.

PRP also involves a clinical procedure, repeated sessions and associated costs. It is not a guaranteed solution, and outcomes vary.

Hair transplantation

For men with established hair loss, transplantation can provide a more substantial and visible change.

Techniques such as follicular unit extraction and follicular unit transplantation move hair follicles from donor areas into regions affected by thinning or baldness.

However, transplantation does not remove the underlying genetic susceptibility of the remaining hair. Existing hair can continue to thin, and some patients require ongoing treatment or further procedures.

Surgical restoration also depends on donor supply, the pattern of hair loss, the skill of the surgeon and realistic expectations.

The key distinction is that transplantation redistributes follicles, whereas pharmaceutical and topical approaches attempt to preserve or improve the hair that remains.

The emerging category of regenerative hair care

This is where treatments involving growth factors, cell-derived signalling molecules and exosome-associated technologies enter the conversation.

They aim to influence biological processes involved in tissue maintenance and repair rather than simply coating the hair shaft or changing its appearance.

The science is interesting, but the category is broad. Products differ in their biological source, composition, processing, delivery method and supporting evidence.

A result obtained with one preparation cannot automatically be applied to another. Nor does the word exosome guarantee that a product contains a clinically effective quantity of biologically active material.

This is precisely why I want to look closely at Calecim itself rather than relying on the wider excitement surrounding regenerative medicine.

Enter Calecim Professional: why this product caught my attention

Calecim Professional occupies an interesting position between cosmetic hair care and regenerative biotechnology.

The company developed its PTT-6 technology from research involving cells obtained from the lining of the umbilical cord. According to Calecim, the resulting proprietary material contains cell-derived signalling molecules, including proteins, growth factors and exosome-associated components.

What caught my attention is the idea that the product is designed around the biological environment of the hair follicle rather than simply the appearance of the hair itself.

That does not establish that it will reverse androgenetic alopecia. But it does give us a mechanism to examine.

The important question is what PTT-6 contains, what it is proposed to do and how much evidence exists that those effects translate into meaningful improvements in human hair.

What exactly is PTT-6?

Calecim describes PTT-6 as a proprietary complex derived from conditioned culture media associated with umbilical cord lining cells.

In simple terms, cells release a variety of molecules into their surrounding environment. These can include proteins and signalling factors involved in communication between cells.

Conditioned media is the material collected from a cell-culture environment after cells have released such substances. It can contain a mixture of biological components, depending on how it is produced and processed.

Calecim's PTT-6 is not a preparation of live stem cells. The company's published descriptions identify it as a cell-derived mixture containing proteins, growth factors, cytokines and exosome-associated material. Its ingredient information also lists components such as fibronectins, glycoproteins, albumin, collagens and hyaluronic acid. ⁴

These components do not all perform the same function.

Growth factors are signalling proteins that can influence processes such as cell proliferation, differentiation and tissue repair. Cytokines are signalling molecules involved in communication between cells, including immune and inflammatory pathways. Fibronectins and other extracellular-matrix-associated proteins contribute to the structural and signalling environment surrounding cells.

Exosomes are a type of extracellular vesicle: small membrane-bound structures released by cells that can transport biological cargo, including proteins and other molecules.

In laboratory research, extracellular vesicles have attracted interest because they participate in cell-to-cell communication and may influence the behaviour of recipient cells.

The scientific appeal is that tissue function depends not only on the cells themselves, but also on the signals they receive from their surrounding environment.

However, there is an important distinction between identifying biologically active components in a product and demonstrating that a finished topical treatment produces a clinically meaningful effect on male pattern hair loss.

The former can support a plausible mechanism. The latter requires appropriate human evidence.

The science: how could PTT-6 influence hair follicles?

The hair follicle is a highly organised mini-organ containing several interacting cell populations.

Among the most important are dermal papilla cells, located at the base of the follicle, which participate in regulating hair growth. Other cells contribute to the follicular structure, surrounding tissues and cycling process.

The behaviour of these cells is influenced by a network of molecular signals.

This is the biological context in which Calecim's approach becomes interesting.

Rather than targeting DHT directly, PTT-6 is proposed to support cellular communication, follicular activity and the local scalp environment.

There are several mechanisms worth considering.

1. Supporting dermal papilla cell activity

Dermal papilla cells are important regulators of hair-follicle growth. Their signalling activity helps influence the behaviour of surrounding follicular cells and the progression of the hair cycle.

Laboratory experiments can investigate whether a substance influences the proliferation or activity of these cells.

Calecim reports that its PTT-6 preparation increased hair-follicle cell proliferation by 24% in laboratory testing. The company also describes studies conducted with Singapore Polytechnic examining its effects on primary human dermal papilla cells. ⁵

That is an interesting starting point.

But a laboratory result is not the same as a 24% increase in hair growth on a person's scalp.

Cell proliferation in a controlled experiment does not automatically translate into the same response in living tissue. The concentrations used, the experimental conditions and the relationship between the model and the human scalp all matter.

The finding therefore supports a hypothesis about biological activity. It does not, by itself, establish clinical efficacy.

2. Influencing the hair-growth cycle

The hair follicle alternates between growth, regression and rest. One objective of hair-restoration research is to support a healthier growth cycle and increase the proportion of follicles producing visible hair.

Calecim proposes that signalling molecules within PTT-6 can support follicular activity and help maintain the growth phase.

This is biologically plausible as a research direction, given the role of cell-to-cell signalling in follicular regulation.

However, the claim needs to be assessed against the actual human evidence for the finished product.

A substance that changes cellular behaviour in vitro may not necessarily prolong the growth phase in humans. Demonstrating that outcome requires appropriately designed studies that assess the hair cycle or relevant clinical endpoints.

3. Supporting the scalp environment

A healthy scalp provides the environment in which hair follicles operate.

Inflammation, irritation and certain scalp disorders can contribute to hair shedding or interfere with normal hair growth. This does not mean that inflammation is the primary cause of every form of hair loss, nor that androgenetic alopecia can be reduced to an inflammatory condition.

Male pattern baldness is strongly associated with genetic susceptibility and androgen signalling.

Calecim reports laboratory findings suggesting that its PTT-6 preparation can influence inflammatory responses. Its published technology material describes a reduction in an inflammatory marker or response of up to 30-fold in the relevant testing context.

The precise experimental context matters. Without understanding the model, the measured endpoint and the conditions of the experiment, it would be misleading to interpret this as a 30-fold reduction in scalp inflammation in people using the finished product.

Nevertheless, the broader idea of supporting scalp health is relevant.

A well-tolerated product that improves scalp condition may have value even if its effect on androgenetic alopecia proves more modest than its marketing suggests.

4. Exosomes and cellular communication

Exosomes are among the most discussed topics in regenerative medicine.

They are a subset of extracellular vesicles that can carry proteins, lipids and nucleic acids between cells. Researchers are investigating their potential roles in tissue repair, inflammation and regenerative processes.

The appeal is that exosomes may help coordinate biological responses without requiring the transfer of whole cells.

In hair research, scientists are investigating whether extracellular vesicles derived from various cell sources can influence dermal papilla cells, follicular activity and hair-growth signalling.

However, exosome research remains an evolving field. Preparations differ substantially, and their biological activity depends on the source cells, manufacturing process, isolation method, cargo and delivery conditions.

It is therefore essential not to treat all exosome-based products as equivalent.

Calecim's PTT-6 is a proprietary cell-derived mixture rather than a simple, standardised exosome preparation. The presence of exosome-associated components within that mixture does not establish the precise contribution of those components to any observed clinical result.

That is the question I find most interesting: how much of the product's reported effect can be attributed to particular signalling molecules, and how convincingly have those effects been demonstrated in humans?

The answer requires more than an appealing mechanism. It requires product-specific evidence.

What does the clinical evidence actually show?

This is where I think the conversation about Calecim needs to become more rigorous.

The company's published hair-science material reports several findings, including:

• A 24% increase in hair-follicle cell proliferation in laboratory testing.

• A 16% increase in hair-shaft thickness.

• A 14% increase in hair count.

• A 15% increase in the number of active hair follicles per square centimetre.

  
  

The latter three figures are reported in connection with a 12-week human study described by the company.

These findings are interesting, but they need to be interpreted in context.

First, the laboratory result and the human findings are different types of evidence. A laboratory experiment can help investigate biological mechanisms, whereas a human study is needed to understand how a treatment performs on actual scalps.

Second, the reported changes in hair count and thickness are not the same as a demonstrated reversal of male pattern baldness. A statistically measurable change in a hair-related endpoint may be meaningful, but its practical importance depends on the baseline condition, the measurement method and the magnitude of the change.

Third, the study design matters. To judge how confidently a treatment's effect can be attributed to the product, we need to know whether the study was randomised, whether it included an appropriate control group, how many participants completed it, whether assessors were blinded and how outcomes were measured.

Fourth, a 12-week study cannot establish the long-term durability of the result. Male pattern baldness is a progressive condition, and maintaining an improvement over time is a different question from producing a short-term change.

Finally, Calecim's published figures should be understood as company-reported evidence. They are a useful starting point, but independent replication and stronger comparative clinical studies would increase confidence in the findings.

I would therefore describe the evidence as promising but not definitive.

It supports further investigation of the product. It does not yet justify the conclusion that Calecim is as effective as finasteride or minoxidil, or that it can reliably replace either treatment.

My first week: establishing the baseline

I have now completed the first week of the six-week programme.

At this stage, I am deliberately resisting the temptation to look for dramatic changes.

Hair grows slowly, and the visible effects of a treatment cannot be judged reliably from a few days of use. Even if the product influences follicular biology, that does not mean new hair will immediately become visible.

My priority is to establish a consistent routine and create a baseline against which any later changes can be assessed.

That means paying attention to the condition of my scalp, how the product feels to use and whether the application process is practical enough to maintain.

It also means documenting my hair rather than relying on memory.

The most useful baseline photographs are taken under consistent conditions: the same lighting, camera, distance, angle and hairstyle. The frontal hairline, temples, crown and mid-scalp should be photographed separately.

Where possible, hair should be arranged similarly each time, because differences in styling, moisture and lighting can create the illusion of changes in density.

I would also record any other hair-loss treatments I am using. If I introduce several interventions simultaneously, it becomes much harder to understand which, if any, contributed to a change.

For the purposes of this six-week experiment, I want to keep the reporting as transparent as possible.

I will not attribute an improvement to Calecim simply because I happen to notice a better-looking photograph. I want to distinguish between changes in appearance, changes in scalp comfort and evidence of a measurable difference in hair growth.

That distinction is central to the credibility of the review.

The six-week experiment: what I will be measuring

The programme gives me a defined starting point, but the real question is how to evaluate it properly.

I am interested in five outcomes.

Hair density

Does the scalp appear less visible in the areas where I am concerned about thinning?

This is one of the most visually meaningful outcomes, but it is also susceptible to changes in lighting, styling and hair length. Consistent photography is therefore essential.

Hair thickness

Do individual strands appear thicker, and does the hair have more body?

This may be a useful indicator of hair quality, but subjective impressions should be separated from objective measurements of shaft diameter.

Shedding

Does the amount of hair I notice shedding during washing or styling change?

Shedding naturally fluctuates, so I would not interpret a short-term reduction as proof that follicular miniaturisation has stopped. A consistent measurement method would be needed to make this observation more meaningful.

Scalp condition

Does the scalp feel healthier, with less irritation, dryness or discomfort?

This is a separate outcome from regrowth. A product may improve scalp condition without producing a substantial change in hair density, and that distinction should be acknowledged.

Tolerability and convenience

Is the routine comfortable? Does the application process fit into everyday life? Do I experience any irritation or other unwanted effects?

A treatment's practical value depends partly on whether it can be used consistently and safely.

I will also keep in mind that a six-week programme cannot fully establish long-term effectiveness in a progressive condition.

If the results are encouraging, I would want to understand what happens after the initial programme and whether any benefit persists. I would not assume that a six-week course produces a permanent change.

Is Calecim an alternative to finasteride and minoxidil?

This is probably the most important question for anyone considering the product.

My answer, based on the evidence currently available, is that I would regard Calecim as an emerging approach to hair and scalp care rather than a proven replacement for established male pattern hair-loss treatments.

Finasteride and minoxidil have a much larger body of clinical evidence supporting their use in androgenetic alopecia. Their benefits and limitations are comparatively well characterised.

Calecim's PTT-6 technology is interesting because it explores a different biological pathway, but its published evidence is more limited. The available findings do not establish that the treatment prevents the progression of androgenetic alopecia to the same extent as finasteride or produces equivalent regrowth to minoxidil.

That does not mean it has no value. It means its value remains a question to investigate.

Men who are concerned about the potential side effects of conventional treatments should discuss the options with a dermatologist or qualified prescriber. Depending on the diagnosis, medical history and personal priorities, there may be different ways to approach treatment.

It is also important to remember that not all hair loss is androgenetic alopecia. Sudden shedding, patchy loss, scalp inflammation or changes associated with illness, nutritional deficiencies or other conditions may require a different assessment.

A product marketed for thinning hair should not be used as a substitute for establishing the cause of hair loss.

For now, the experiment has begun. The verdict will come after six weeks, and I intend to let the evidence—not the promise—tell the story.